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responsibility of XAbstract A highly sensitive ultra-high-performance liquid chromatographic–tandem mass spectro-
metry (UPLC/MS/MS) method was developed for the quantiﬁcation of the synthetic peptide drug
of exenatide in monkey plasma. Sample preparation was carried out by solid-phase extraction
(SPE), and bivalirudin was used as the internal standard (IS). An excellent chromatographic
separation was obtained on a reversed-phase C18 column with a gradient elution. Detection utilized
a Qtrap 5500 system operated in the positive ion mode with multiple reaction monitoring (MRM).
The proposed method was validated by assessing the speciﬁcity, linearity, intra- and inter-day
precision and accuracy, recovery, and stability. The method resulted in a linear calibration range of
0.10–30 ng/mL, extracting with only 50 mL monkey plasma aliquots. The intra- and inter-day
precisions (as relative standard deviation) were less than 7.5% and 9.6%, respectively. The methodersity. Production and hosting by Elsevier B.V. All rights reserved.
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J.-F. Zhang et al.236could be successfully utilized for the pharmacokinetic study of exenatide in monkeys following a
single subcutaneous injection of Byetta.
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There has been an increasing incidence of type 2 diabetes in
the world population recently. The use of traditional
therapies for type 2 diabetes to achieve adequate glycaemic
control was often limited by undesired hypoglycemic
and weight gain. Moreover, it has been witnessed that
sustained development of antidiabetic therapies exploits
the enteroinsular axis. Exenatide (synthetic exendin-4), a
human glucagon-like peptide-1 (GLP-1) analogue with a
molecular weight of 4186.6 Da, is the ﬁrst member of the
class of GLP-1 receptor agonists [1–4]. It mimics the action
of the human hormone GLP-1 that plays a major role in
the maintenance of glucose homoeostasis [5], which could
improve the glycaemic control through enhancing the
glucose-dependent insulin secretion, suppressing the inap-
propriately elevated postprandial glucagon secretion, slow-
ing the gastric emptying, and reducing the food intake with
the result of bodyweight reducing [6,7].
Exenatide has a longer half-life (about 2.4 h) than GLP-1
(less than 2 min) with no rebound effect until the termination
of administration. The clinical use of exenatide still requires
daily (two times a day) repeated subcutaneous injections.
Recently, a slow release form of exenatide has been investi-
gated that only requires weekly intramuscular injections,
which exhibits good acceptability and compliance in clinical
use [8].
To date, various methods have been developed for the
quantitation of exenatide, such as immunoassay (ELISA) [8,9]
and high-performance liquid chromatographic–tandem mass
spectrometry (HPLC/MS/MS) method [10,11]. However, ana-
lytical ranges used in ELISA are typically limited to one to
two orders of magnitude. And sometimes ELISA has poor
repeatability and speciﬁcity [12]. The immunoassay methodol-
ogies also have potential interferences from endogenous
compounds and require expensive antibodies and special
reagents that are often difﬁcult to obtain, which signiﬁcantly
lengthens the method development time and increases the cost
of the experiment [11]. Compared with immunoassay meth-
odologies, the method of UPLC/MS/MS for peptide quanti-
tative research is potential and worthy of further exploration.
The previous HPLC/MS/MS method for exenatide has a
linear calibration range of 20–2000 ng/mL requiring 150 mL
of blood plasma [10], although its lower limit of quantitation
(LLOQ) was limited to quantitate the effective concentration
of pharmacology.
Therefore, in the present study, we investigated a rapid and
sensitive UPLC/MS/MS method for the determination of
exenatide levels in monkey plasma and applied this method
to the evaluation of Byetta after the subcutaneous injection of
5 mg for each animal. For the ﬁrst time, the UPLC/MS/MS
method is performed for the determination of the plasma
concentration of exenatide with lower LLOQ (0.10 ng/mL),
which has great future potential to be used for the monkey
and human pharmacokinetics study.2. Experimental
2.1. Reagents and chemicals
Exenatide (purity497%) was supplied by BACHEM, Inc
(Torrance, USA). Bivalirudin (purity487%) for using as the
internal standard (IS) was purchased from Shanghai TASH
Biotechnology Co., Ltd. Methanol and acetonitrile are HPLC
grade, purchased from Merck KGaA. Formic acid (98%)
was purchased from Fluka (Buchs, Switzerland). Ammonium
hydroxide (25.0–28.0%) was purchased from LaiYang
ShuangXing Chemical Co., Ltd (Shandong, China). Oasiss
MCX (30 mg, 1 cc) was purchased from Waters Corporation
(Milford, MA, USA). Deionized (DI) water was generated
from Milli-Q water purifying system purchased from Millipore
Corporation (MA, USA).
2.2. Instrumentation and chromatographic conditions
The UPLC/MS/MS system consisted of an Agilent 1290 series
HPLC system (Agilent Technologies, Palo Alto, CA, USA)
coupled to an Applied Biosystems Sciex Qtrap 5500 mass
spectrometer (Applied Biosystems Sciex, Ontario, Canada)
using electrospray ionization (ESI). Chromatography was
performed on a ZORBAX RRHD Eclipse Plus C18 (1.8 mm,
50 mm 2.1 mm) maintained at 40 1C using a gradient elution
with 0.2% formic acid as solvent A and methanol as solvent B.
The gradient involved: 10% B for 1.5 min; a linear increase
from 10% to 90% B in 1.0 min, 90% B for 0.5 min; a linear
decrease from 90% to 10% B in 0.1 min; and equilibration at
10% B for 2.0 min. The ﬂow rate was 0.5 mL/min without
a split.
Multiple reaction monitoring (MRM) at unit resolution
involved transitions of the protonated forms of exenatide at
m/z 1047.4-396.3 and of bivalirudin at m/z 1090.7-650.3 in
the positive ion mode. Full-scan product ion mass spectra of
exenatide and bivalirudin are shown in Fig. 1. Optimized MS
conditions were described as follows: curtain gas, gas 1 and
gas 2 (all nitrogen) with 35, 55 and 55 units, respectively; dwell
time with 100 ms; ion spray voltage with 5500 V; source
temperature with 575 1C; declustering potentials with 240 V
for exenatide and 100 V for bivalirudin; collision energies with
42 eV (m/z 1047.4-396.3) for exenatide and 48 eV for
bivalirudin (m/z 1090.7-650.3).
2.3. Preparation of calibration standards and quality control
(QC) samples
A stock solution of exenatide (1.0 mg/mL) in methanol
(containing 0.1% formic acid) was diluted with methanol/
Milli-Q water/0.1% formic acid (90:10:0.1, v/v/v) to give a
series of standard solutions. A series of calibration standards
were then prepared by spiking blank monkey plasma samples
(50 mL) with 50 mL aliquots of standard solutions to give
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Fig. 1 The product ion scans of [Mþ4H]4þ for exenatide (A) and
[Mþ2H]2þ for bivalirudin (B).
UPLC–MS/MS for the determination of exenatide in monkey plasma 237exenatide concentrations in plasma of 0.10, 0.30, 0.50, 1.0, 3.0,
10 and 30 ng/mL, respectively. Quality control (QC) samples
at three concentrations (0.20, 2.0 and 24 ng/mL) were pre-
pared independently by the same procedure. Stock solution of
the internal standard (IS, bivalirudin; 1.0 mg/mL) was
also prepared in methanol (containing 0.1% formic acid).
A working IS solution (bivalirudin, 8.5 ng/mL) was obtained
by dilution of the bivalirudin stock solution with methanol/
Milli-Q water/0.1% formic acid (90:10:0.1, v/v/v).
2.4. Sample preparation
All frozen monkey plasma samples were thawed at room
temperature and subjected to SPE as follows. An aliquot of
50 mL plasma, 50 mL methanol/Milli-Q water/0.1% formic acid
(90:10:0.1, v/v/v) and 50 mL IS solution were added in the 1.5 mL
Eppendorf tube. The mixture was vortex-mixed for 1 min and
then centrifugated at 15000 g for 5 min. After precondition of
1 mL of methanol and 0.5 mL of formic acid (0.5%) in Milli-Q
water, the supernatant was transferred to the Oasiss MCX. The
columns were washed with 0.5% formic acid in Milli-Q water, and
then methanol/2% aqueous formic acid 96:4 (v/v). The analyte
and IS were eluted with two 200 mL portions of acetonitrile/
methanol/Milli-Q water/25% aqueous ammonium hydroxide
(4:1:1:1.0, v/v/v/v) to 10 mL plastic tube. The collection was
added with 200 mL acetonitrile/methanol/Milli-Q water/formic
acid (6:5:1:0.1, v/v/v/v), and then evaporated to dryness at 50 1C
under a gentle stream of nitrogen. The sample was reconstituted in
50 mL methanol/water/0.1% formic acid (90:10:0.1, v/v/v) and
vortexed for 30 s. A 10 mL aliquot of the sample solution was
injected into the UPLC/MS/MS system.
2.5. Method validation
Assay validation was performed according to the FDA guide-
lines [13]. Speciﬁcity was performed by analyzing blank
plasma samples from six different subjects. Three independentstandard curves and six replicates of low, medium and high
QC samples were analyzed on three different days. Linearity
was analyzed by weighted linear regression (1/x2) of analyte-
internal standard peak area ratios. The precision (represented
by the relative standard deviation, RSD) and the accuracy
(represented by the relative error, RE) were evaluated based
on assay of the LLOQ, QC samples in three consecutive days,
six replicates for each day. Recovery was determined by
comparing peak areas of QC samples with those of post-
extraction spiked blank plasma. Matrix effects were evaluated
by comparing peak areas of the analyte in QC post-extraction
spiked blank plasma samples with those in standard solutions.
Stability tests were conducted to evaluate the analyte
stability in stock solutions and in plasma samples under
different conditions. Stock solution stability was determined
by the area response of analyte (at 40 1C) and internal
standard (at 4 1C) in the stability samples with that comparing
of samples prepared from fresh stock solution. Room tem-
perature stability (2 h), processed samples stability (reinjection
stability at room temperature for 12 h), freeze-thaw stability
(three cycles), long-term stability at 40 1C (1 month) were
performed at QC samples using three replicates at each level.
Samples were considered to be stable if assay values were
within the acceptable limits of accuracy (715% SD) and
precision (r15% RSD).
2.6. Application of the method to a pharmacokinetic
study in monkey
Animal studies were all performed under the instruction of
protocols required by the Animal Care and Use Committee of
the Chinese Academy of Medical Sciences.
The experiment was led by West China Hai-Qi Medical
Technology Co., Ltd. Three male healthy monkeys (3.5–4.0 kg)
were given subcutaneous injection of the same dose of Byetta
(5 mg for each monkey). Blood samples (0.5 mL at each time
point) were collected from the hind limbs vein prior to dosing
and at 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h and
24 h after dosing. Blood samples were centrifuged and plasma
was separated and stored at 40 1C until analysis. The plasma
concentration–time proﬁles for exenatide in each subject were
analyzed by noncompartmental analysis using DAS 2.1.3. Results and discussion
3.1. Mass spectrometry
The [Mþ4H]4þ of exenatide was selected as the precursor ion
(m/z 1047.4) because it was the principal charged species
observed in the Q1 scan process. The corresponding
[Mþ2H]2þ of bivalirudin (m/z 1090.7) was chosen for the
same reason. Accordingly, the transition m/z 1047.4-396.3
was selected as quantiﬁer. The transition m/z 1090.7-650.3
was used to bivalirudin.
3.2. Method development
Various mobile phase combinations of acetonitrile, methanol,
ammonium acetate and formic acid were investigated to optimize
the chromatography for sensitivity, speed and peak shape.
J.-F. Zhang et al.238Methanol gave a better response than acetonitrile and the peak
shape was improved by the addition of formic acid. The
ZORBAX RRHD Eclipse Plus C18 (1.8 mm, 50 mm 2.1 mm)
was chosen because it gave the best resolution and peak shapes
with minimal matrix effects. At the same time, we found that the
dilution of exenatide had a great effect on the signal intensity and
that the acidity of the dilution gave great contribution to the
stability of exenatide. The dilution was ﬁnally conﬁrmed as the
methanol/Milli-Q water/0.1% formic acid (90:10:0.1, v/v/v).
Isolation of exenatide from plasma is a tedious task,
because of the low concentration levels and interferences
induced by matrix. The result of protein precipitation was
not comforting [14], which should be related to the relatively
big size of the peptide drug that leads to the co-precipitation of
exenatide. The recovery of reverse phase liquid–liquid extrac-
tion was low, which might be due to the related properties of
amphoteric compound. According to the information, various
solid-phase extractions (Waters Oasiss HLB, Waters Oasiss
MCX, Waters Oasiss WAX) were investigated. Sample
prepared by HLB and WAX showed the poor recovery.
Oasiss MCX with appropriate condition of elution provided
better recovery and less remaining endogenous interferences.
The percentage of formic and aqueous ammonium in the
elutions was a key factor. Glass tube and plastic tube were also
investigated as the receiving vessel, and the results indicated
that the glass tube had high adsorption of exenatide. It should
be suggested that exenatide contained more acidic amino acids
leading to the more easily glass adsorption [15,16].
A number of potential internal standards including triptor-
elin, elcatonin, and diazepam were evaluated in the present
study, while most of them were incompatible with the sample
preparation procedure because of their physicochemical prop-
erties. Finally, bivalirudin was chosen for the suitable IS for its
similar physicochemical characteristics and similar retention
time. It could be presumed that bivalirudin and exenatide had
more acidic amino acid than basic amino acid in their
structures while some others went in the opposite direction.
Moreover, the results of our study showed that the pH ofMax. 140.0 cps.
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Fig. 2 Representative MRM chromatograms of exenatide (m/z 1047.4
dog and rat).compounds was an important factor in the complex elution
systems of MCX column.
Blank plasma of several animals including rat, dog, monkey
and human were compared; however, there was no inter-
ference with the endogenous substances only in the blank
monkey and human plasma as shown in Fig. 2, which might
be caused by the different kinds and contents of GLP-1 and its
analogues in various species plasma.3.3. Method validation
3.3.1. Selectivity and chromatography
The assay was found to be highly speciﬁc since there were no
endogenous peaks in monkey plasma at the retention times of
IS and exenatide. Representative chromatograms of blank
plasma and blank plasma spiked with exenatide at the LLOQ
(0.10 ng/mL) were shown in Fig. 3.3.3.2. Linearity
Calibration curves were prepared using seven standards, and it
was linear in the range of 0.10–30 ng/mL. The mean correla-
tion coefﬁcient (r2) was greater than 0.9986 for all curves.3.3.3. Precision and accuracy
As shown in Table 1, the precision and accuracy of exenatide
in the intra- and inter-day runs were within 715% at LOQ,
MOQ, and HOQ concentrations and within 720% at
LLOQ QCs.3.3.4. Extraction efﬁciency
The recoveries of exenatide and the IS were good and
reproducible. Recoveries of exenatide from the low, medium
and high QC samples were 65.172.1%, 63.273.3% and
62.573.0%, respectively. The recovery of bivalirudin was
69.474.4%.Max. 130.0 cps.
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Fig. 3 Representative MRM chromatograms of exenatide and bivalirudin in monkey plasma. (A) Blank plasma; (B) blank plasma
spiked with 0.1 ng/mL of exenatide (I) and 8.5 ng/mL bivalirudin (II); (C) plasma sample from a monkey volunteer 15 min of exenatide
after the subcutaneous injection of exenatide (5 mg for each monkey).
Table 1 Precision and accuracy for the determination of exenatide in monkey plasma (data are based on assay of six replicates
on three different days).
Spiked conc. (ng/mL) Calculated conc.
(mean7SD, ng/mL)
Intra-day precision
(RSD, %)
Inter-day precision
(RSD, %)
Accuracy
(RE, %)
0.10 0.1070.01 7.0 3.1 0.4
0.20 0.2070.01 2.5 7.5 1.9
2.00 1.9570.14 7.1 9.3 2.7
24.00 22.7671.66 6.9 9.6 5.2
UPLC–MS/MS for the determination of exenatide in monkey plasma 2393.3.5. Matrix effect
The matrix effects were shown to be minimal based on the
ratios of the peak areas for exenatide in the low, medium and
high post-extraction spiked blank plasma samples to the peak
areas in the corresponding standard solutions; these ratios
were 105.774.0%, 103.677.0% and 105.372.0%, respec-
tively. Similarly the ratio of bivalirudin was 105.078.3%.3.3.6. Stability
The stock solutions of exenatide were stable at 40 1C for at
least one month and IS solutions were stable at 4 1C for at
least three months.
Room temperature stability, reinjection stability, freeze-
thaw stability and long-term stability for exenatide were
investigated at the low, medium and high QC samples. The
results revealed that exenatide was stable under all of the
conditions examined (Table 2).3.4. Pharmacokinetic study
The mean concentration–time proﬁle of exenatide after the
subcutaneous injection of exenatide is shown in Fig. 4. The
mean peak plasma concentration (Cmax) was 2.0570.38 ng/mL
at a time (Tmax) of 0.5 h after the injection was given. The mean
area under the plasma concentration–time curve (AUC0-t) was
5.0670.72 ng  h/mL and the mean elimination half-life (t1/2) was
1.2270.24 h.4. Conclusion
In summary, a highly sensitive and selective UPLC/MS/MS
method was ﬁrst developed for the determination of exenatide
in monkey plasma, which had the LLOQ of 0.10 ng/mL and
good accuracy and precision. The lower requirement of
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Fig. 4 Plasma concentration–time proﬁle of subcutaneous injec-
tion of exenatide (5 mg for each monkey) to healthy monkey. Data
are mean7SD for three monkeys (three males).
Table 2 Stability of exenatide under various conditions (data are mean7SD of three replicates).
Storage conditions Initial conc. (ng/mL) Final conc. (ng/mL) RE (%)
Monkey plasma at room temperature for 2 h 0.20 0.2170.01 2.8
2.00 1.9270.11 4.0
24.00 23.5370.06 2.2
Processed samples at room temperature for 12 h 0.20 0.2170.01 2.8
2.00 2.0770.11 3.5
24.00 24.5771.85 2.4
Monkey plasma after three freeze/thaw cycles 0.20 0.2170.01 4.5
2.00 1.9370.12 3.3
24.00 23.7771.53 1.0
Monkey plasma for one month at 40 1C 0.20 0.1970.01 2.5
2.00 1.9270.11 3.8
24.00 23.2071.04 3.3
J.-F. Zhang et al.240monkey plasma volume was only 50 mL, which provided the
possibility for repeated analyses without increasing blood
volumes. Because there was also no interference with the
endogenous substances in human plasma, this method could
be well applicable to the clinical pharmacokinetic research.
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